Sutro Biopharma, Inc. (STRO)
21.39
+0.90
(+4.39%)
USD |
NASDAQ |
Aug 25, 16:00
21.39
0.00 (0.00%)
After-Hours: 19:59
Sutro Biopharma Gross Profit Margin (Quarterly) : 87.17% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 87.17% |
| March 31, 2026 | 91.20% |
| December 31, 2025 | 86.06% |
| September 30, 2025 | 80.40% |
| June 30, 2025 | 97.02% |
| March 31, 2025 | 89.08% |
| December 31, 2024 | 87.39% |
| September 30, 2024 | 78.88% |
| June 30, 2024 | 93.04% |
| March 31, 2024 | 86.46% |
| December 31, 2023 | 98.48% |
| September 30, 2023 | 89.72% |
| June 30, 2023 | 77.00% |
| March 31, 2023 | 82.20% |
| December 31, 2022 | 75.00% |
| September 30, 2022 | 91.72% |
| June 30, 2022 | 92.69% |
| Date | Value |
|---|---|
| March 31, 2022 | 0.00% |
| December 31, 2021 | 77.45% |
| September 30, 2021 | 0.00% |
| June 30, 2021 | 0.00% |
| March 31, 2021 | 0.00% |
| December 31, 2020 | 0.00% |
| September 30, 2020 | 0.00% |
| June 30, 2020 | 0.00% |
| March 31, 2020 | 0.00% |
| December 31, 2019 | 0.00% |
| September 30, 2019 | 0.00% |
| June 30, 2019 | 0.00% |
| March 31, 2019 | 0.00% |
| December 31, 2018 | 0.00% |
| September 30, 2018 | 0.00% |
| December 31, 2017 | 0.00% |
| September 30, 2017 | 0.00% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Praxis Precision Medicines, Inc. | -- |
| Upstream Bio, Inc. | 93.53% |
| ACADIA Pharmaceuticals, Inc. | 90.81% |
| Alnylam Pharmaceuticals, Inc. | 76.88% |
| Anika Therapeutics, Inc. | 65.15% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Assets | -83.45% |
| Return on Invested Capital | -119.9% |
| Profit Margin (Quarterly) | -391.6% |
| Operating Margin (Quarterly) | -301.7% |
| Return on Net Operating Assets | -609.7% |